Evonik Strengthens Its Position in Pharmaceutical Industry

  • Author: ChemistryViews
  • Published: 01 March 2011
  • Source / Publisher: Evonik
  • Associated Suppliers: Evonik Industries AG, Essen, Germany
thumbnail image: Evonik Strengthens Its Position in Pharmaceutical Industry

Evonik Industries formally acquired the entire RESOMER® business of Boehringer Ingelheim Pharma GmbH & Co. KG on March 1, 2011. This acquisition involved transferring the entire product portfolio comprising standard and customer-specific polymers for medical applications and pharmaceutical formulations to Evonik’s Pharma Polymers Business Line. The purchase agreement was signed in December 2010. The companies agreed not to disclose details of the purchase price.

In recent years, Evonik has strengthened its position as a producer of active pharmaceutical substances. In the United States, it took over Eli Lilly’s more than 600-employee-strong Tippecanoe site. A new medical products plant has been built in Nanning, China.


Article Views: 2195

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

1 Comments

taylor star wrote:

Pharmaceutical industry

There is a lot of discussion about the state of medical care in the U.S. The doctor-patient relationship is heavily emphasized, for instance. There is an issue concerning physicians and their prescription practices which has been somewhat muted. Several accuse doctors of accepting pharmaceutical business kickbacks in order to recommend certain medications, and not always to the benefit of the patients. This issue has been ongoing for some time. It is getting to the point that the medical industry as a whole is said to be rife with corruption. The proof is here: Pharmaceutical kickbacks continue to plague medical industry .

Wed May 11 07:22:03 UTC 2011

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH